Bioverativ (NASDAQ:BIVV) had its price target hoisted by Royal Bank of Canada to $68.00 in a research note released on Thursday. The firm currently has a market perform rating on the biotechnology company’s stock.
Several other analysts have also weighed in on BIVV. Jefferies Group increased their price target on Bioverativ to $79.00 and gave the company a buy rating in a report on Thursday. Credit Suisse Group restated a neutral rating and set a $65.00 price target on shares of Bioverativ in a report on Thursday. Morgan Stanley restated an underweight rating and set a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Argus upgraded Bioverativ from a hold rating to a buy rating and set a $64.00 price target on the stock in a report on Wednesday, September 20th. Finally, Piper Jaffray Companies restated an overweight rating and set a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Bioverativ currently has an average rating of Hold and an average price target of $62.53.
Bioverativ (NASDAQ BIVV) traded up $1.36 during trading hours on Thursday, reaching $64.11. The company had a trading volume of 712,830 shares, compared to its average volume of 994,808. Bioverativ has a one year low of $40.99 and a one year high of $65.09. The stock has a market cap of $6,940.00 and a price-to-earnings ratio of 15.67.
A number of hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN purchased a new stake in Bioverativ in the third quarter worth $124,500,000. Woodford Investment Management Ltd purchased a new stake in Bioverativ in the third quarter worth $85,455,000. Jackson Square Partners LLC purchased a new stake in Bioverativ in the third quarter worth $99,336,000. Old Mutual Global Investors UK Ltd. purchased a new stake in Bioverativ in the third quarter worth $96,827,000. Finally, ValueAct Holdings L.P. purchased a new stake in Bioverativ in the third quarter worth $72,514,000. Institutional investors and hedge funds own 96.03% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/19/royal-bank-of-canada-boosts-bioverativ-bivv-price-target-to-68-00.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.